BioInvent International AB (publ) (BINV.ST)
SEK 27.85
(3.34%)
SEK 27.85
(3.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -330.3 Million SEK | -869.06% |
| 2022 | -34.08 Million SEK | 87.78% |
| 2021 | -278.96 Million SEK | -263.85% |
| 2020 | -76.66 Million SEK | 44.89% |
| 2019 | -139.11 Million SEK | -12.95% |
| 2018 | -123.16 Million SEK | -22.52% |
| 2017 | -100.52 Million SEK | -60.62% |
| 2016 | -62.58 Million SEK | 30.98% |
| 2015 | -90.68 Million SEK | -67.97% |
| 2014 | -53.98 Million SEK | -199.27% |
| 2013 | -18.03 Million SEK | 90.4% |
| 2012 | -187.84 Million SEK | -180.14% |
| 2011 | -67.05 Million SEK | 47.78% |
| 2010 | -128.4 Million SEK | 27.32% |
| 2009 | -176.66 Million SEK | -1187.08% |
| 2008 | 16.25 Million SEK | 200.98% |
| 2007 | -16.09 Million SEK | 85.21% |
| 2006 | -108.83 Million SEK | 22.19% |
| 2005 | -139.86 Million SEK | -51.18% |
| 2004 | -92.51 Million SEK | -203.19% |
| 2003 | 89.66 Million SEK | 94.21% |
| 2002 | 46.16 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -97.24 Million SEK | 29.18% |
| 2024 Q1 | -77.94 Million SEK | 19.77% |
| 2024 Q2 | -137.3 Million SEK | -76.16% |
| 2023 Q3 | -71.08 Million SEK | 19.54% |
| 2023 Q2 | -88.34 Million SEK | -48.96% |
| 2023 Q1 | -59.3 Million SEK | 31.42% |
| 2023 FY | -330.3 Million SEK | -869.06% |
| 2023 Q4 | -97.15 Million SEK | -36.69% |
| 2022 Q2 | 167.44 Million SEK | 349.15% |
| 2022 FY | -34.08 Million SEK | 87.78% |
| 2022 Q4 | -86.47 Million SEK | -47.61% |
| 2022 Q3 | -58.58 Million SEK | -134.99% |
| 2022 Q1 | -67.2 Million SEK | 14.67% |
| 2021 Q4 | -78.76 Million SEK | -25.8% |
| 2021 Q2 | -57.29 Million SEK | 28.2% |
| 2021 FY | -278.96 Million SEK | -263.85% |
| 2021 Q3 | -62.6 Million SEK | -9.28% |
| 2021 Q1 | -79.78 Million SEK | -379.76% |
| 2020 Q1 | -32.64 Million SEK | 20.27% |
| 2020 Q2 | -39.33 Million SEK | -20.5% |
| 2020 Q4 | 28.52 Million SEK | 186.75% |
| 2020 Q3 | -32.87 Million SEK | 16.42% |
| 2020 FY | -76.66 Million SEK | 44.89% |
| 2019 Q1 | -27.77 Million SEK | 15.02% |
| 2019 FY | -139.11 Million SEK | -12.95% |
| 2019 Q3 | -37.12 Million SEK | -13.18% |
| 2019 Q4 | -40.94 Million SEK | -10.28% |
| 2019 Q2 | -32.79 Million SEK | -18.11% |
| 2018 Q1 | -24.9 Million SEK | 25.18% |
| 2018 Q2 | -43.22 Million SEK | -73.53% |
| 2018 FY | -123.16 Million SEK | -22.52% |
| 2018 Q3 | -22.35 Million SEK | 48.27% |
| 2018 Q4 | -32.67 Million SEK | -46.16% |
| 2017 Q4 | -33.29 Million SEK | -55.35% |
| 2017 Q3 | -21.42 Million SEK | 8.7% |
| 2017 Q1 | -22.33 Million SEK | -206.66% |
| 2017 FY | -100.52 Million SEK | -60.62% |
| 2017 Q2 | -23.47 Million SEK | -5.08% |
| 2016 FY | -62.58 Million SEK | 30.98% |
| 2016 Q3 | -28.54 Million SEK | -5.35% |
| 2016 Q2 | -27.09 Million SEK | -8384.4% |
| 2016 Q1 | 327 Thousand SEK | 101.55% |
| 2016 Q4 | -7.28 Million SEK | 74.48% |
| 2015 Q4 | -21.09 Million SEK | 6.73% |
| 2015 FY | -90.68 Million SEK | -67.97% |
| 2015 Q3 | -22.61 Million SEK | 10.3% |
| 2015 Q2 | -25.21 Million SEK | -15.88% |
| 2015 Q1 | -21.75 Million SEK | 23.57% |
| 2014 Q2 | 3.71 Million SEK | 119.62% |
| 2014 Q4 | -28.46 Million SEK | -176.44% |
| 2014 Q1 | -18.93 Million SEK | -192.52% |
| 2014 FY | -53.98 Million SEK | -199.27% |
| 2014 Q3 | -10.29 Million SEK | -377.28% |
| 2013 Q4 | 20.46 Million SEK | 238.09% |
| 2013 Q2 | -9.42 Million SEK | 33.91% |
| 2013 FY | -18.03 Million SEK | 90.4% |
| 2013 Q1 | -14.25 Million SEK | 33.52% |
| 2013 Q3 | -14.81 Million SEK | -57.25% |
| 2012 Q1 | -36.83 Million SEK | 37.75% |
| 2012 Q3 | -37.24 Million SEK | 59.59% |
| 2012 Q4 | -21.44 Million SEK | 42.4% |
| 2012 FY | -187.84 Million SEK | -180.14% |
| 2012 Q2 | -92.14 Million SEK | -150.2% |
| 2011 Q4 | -59.16 Million SEK | -65.92% |
| 2011 Q3 | -35.65 Million SEK | -13.85% |
| 2011 Q2 | -31.31 Million SEK | -153.01% |
| 2011 Q1 | 59.08 Million SEK | 239.19% |
| 2011 FY | -67.05 Million SEK | 47.78% |
| 2010 FY | -128.4 Million SEK | 27.32% |
| 2010 Q4 | -42.44 Million SEK | -68.13% |
| 2010 Q3 | -25.24 Million SEK | -10.86% |
| 2010 Q2 | -22.77 Million SEK | 39.97% |
| 2010 Q1 | -37.93 Million SEK | 17.24% |
| 2009 Q3 | -42.6 Million SEK | 20.38% |
| 2009 Q2 | -53.5 Million SEK | -54.07% |
| 2009 FY | -176.66 Million SEK | -1187.08% |
| 2009 Q4 | -45.83 Million SEK | -7.59% |
| 2009 Q1 | -34.72 Million SEK | 0.0% |
| 2008 FY | 16.25 Million SEK | 200.98% |
| 2007 FY | -16.09 Million SEK | 85.21% |
| 2006 FY | -108.83 Million SEK | 22.19% |
| 2005 FY | -139.86 Million SEK | -51.18% |
| 2004 FY | -92.51 Million SEK | -203.19% |
| 2003 FY | 89.66 Million SEK | 94.21% |
| 2002 FY | 46.16 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 2cureX AB (publ) | -32.51 Million SEK | -915.757% |
| Abliva AB (publ) | -95.5 Million SEK | -245.835% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -202.233% |
| AcouSort AB (publ) | -17.08 Million SEK | -1832.846% |
| Active Biotech AB (publ) | -45.8 Million SEK | -621.188% |
| Alzinova AB (publ) | -16.48 Million SEK | -1904.272% |
| Amniotics AB (publ) | -30.87 Million SEK | -969.984% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -649.771% |
| Aptahem AB (publ) | -11.11 Million SEK | -2872.266% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -2474.867% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -32.873% |
| BioArctic AB (publ) | 229.24 Million SEK | 244.081% |
| Biosergen AB | -27.03 Million SEK | -1121.674% |
| Biovica International AB (publ) | -124.82 Million SEK | -164.618% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -481.306% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 29.147% |
| Camurus AB (publ) | 431.44 Million SEK | 176.558% |
| Cantargia AB (publ) | -280.02 Million SEK | -17.954% |
| Corline Biomedical AB | -1.8 Million SEK | -18158.928% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1466.09% |
| CombiGene AB (publ) | -35.66 Million SEK | -826.119% |
| Cyxone AB (publ) | -22.98 Million SEK | -1336.792% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2728.43% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -117.52% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | -1.041% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1914.297% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -261.379% |
| Fluicell AB (publ) | -26.55 Million SEK | -1143.895% |
| Genovis AB (publ.) | 61.5 Million SEK | 637.08% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -191.471% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 60.287% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -168.391% |
| Mendus AB (publ) | -101.61 Million SEK | -225.042% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -85.732% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -791.004% |
| I-Tech AB | 20.2 Million SEK | 1734.926% |
| Intervacc AB (publ) | -102.85 Million SEK | -221.145% |
| Kancera AB (publ) | -64.88 Million SEK | -409.029% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 6232.64% |
| LIDDS AB (publ) | -40.2 Million SEK | -721.529% |
| Lipum AB (publ) | -37.17 Million SEK | -788.439% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -2623.483% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2814.307% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1745.583% |
| Nanologica AB (publ) | -75.15 Million SEK | -339.485% |
| NextCell Pharma AB | -41.95 Million SEK | -687.191% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -32.593% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1977.122% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -3226.321% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1899.056% |
| Saniona AB (publ) | -95.81 Million SEK | -244.749% |
| Simris Alg AB (publ) | -37.3 Million SEK | -785.415% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -682.285% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -75311.872% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1291.516% |
| SynAct Pharma AB | -215.81 Million SEK | -53.053% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | -6.227% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 14.908% |
| Xintela AB (publ) | -54.08 Million SEK | -510.735% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -83.842% |
| Ziccum AB (publ) | -21.41 Million SEK | -1442.612% |